Why Your Heart Rate Rises on a GLP-1, and When It Matters

GLP-1 medications raise resting heart rate a little, and the FDA labels say so plainly. On average it's a few beats per minute, which most people never notice. Some people see bigger increases, and the Wegovy label asks clinicians to monitor heart rate and to stop the drug if a sustained rise occurs. Knowing your baseline and the symptoms worth reporting is the practical takeaway.

Here's what each label reports, why it happens, how it squares with the cardiovascular benefits, and when it's worth a call.

What the labels report

For adolescents on Wegovy with a normal starting heart rate, the label reports a maximum increase of 20 bpm or more in 54% vs. 39% on placebo.

How to read the "maximum change" numbers

The Wegovy figures for 10–19 and 20+ bpm describe the largest single change from baseline recorded during the trial, not a steady new level. Heart rate naturally swings with activity, stress, caffeine, and sleep, which is why the placebo group also had big maximum changes. The gap between groups is what reflects the drug.

The Mounjaro label's sinus tachycardia figures are a useful contrast. They show the higher dose roughly doubling the rate of episodes compared with placebo. The label also notes higher rates in Japanese patients, reaching 23% at 15 mg.

Where it sits in the label

The labels don't treat this effect identically. Wegovy lists heart rate increase as a formal warning and precaution. It tells clinicians to monitor heart rate at regular intervals, to stop Wegovy if a sustained increase in resting heart rate occurs, and to instruct patients to report palpitations or a racing heartbeat at rest.

Zepbound's label covers heart rate in the adverse reactions section rather than the warnings list. MedlinePlus, the NIH's consumer drug information service, lists "rapid or pounding heartbeat" among semaglutide symptoms that warrant calling a doctor right away. Cleveland Clinic includes mild tachycardia in its list of GLP-1 side effects.

Why it happens

The leading explanation is that GLP-1 acts directly on the heart. A 2024 study in Cardiovascular Research by Lubberding and colleagues at the University of Copenhagen found that GLP-1 still raised heart rate in pigs even after the researchers blocked the nerves and hormone signals that normally speed the heart. The authors concluded that GLP-1 has a direct effect on GLP-1 receptors in the sinus node, the heart's natural pacemaker.

That was an animal study, so it doesn't settle everything about humans, but it fits the consistent rise seen across these drugs.

Other factors can push your heart rate higher on top of the drug effect:

• Dehydration. Low fluid intake plus nausea, vomiting, or diarrhea lowers blood volume, and the heart beats faster to compensate. The labels link GI fluid loss to acute kidney injury, so dehydration is worth taking seriously on its own.
• Lower blood pressure. The Wegovy label reports hypotension-related reactions in 1.3% vs. 0.4% on placebo. A drop in pressure can trigger a faster pulse, especially on standing.
• Low blood sugar, mainly if you also take insulin or a sulfonylurea. The labels warn of higher hypoglycemia risk in that combination.
• Caffeine, stimulants, decongestants, poor sleep, illness, and anxiety, the usual suspects.

Does it cancel out the heart benefits?

The best evidence says no, at least for semaglutide in people with established heart disease. The SELECT trial, published in the New England Journal of Medicine in 2023 by Lincoff and colleagues, randomized 17,604 adults aged 45 and older with overweight or obesity and established cardiovascular disease, without diabetes, to semaglutide 2.4 mg or placebo. Over a mean follow-up of about 40 months, major adverse cardiovascular events occurred in 6.5% on semaglutide vs. 8.0% on placebo, a 20% relative reduction (hazard ratio 0.80).

That benefit came despite the known heart rate effect. It doesn't mean heart rate doesn't matter for an individual, but it does mean a small average rise shouldn't by itself be read as a sign of harm. For more on the cardiovascular evidence, see our SELECT trial breakdown.

Who should pay closer attention

The labels don't list specific cardiac conditions that rule out treatment because of heart rate, so these are reasons to discuss monitoring with your clinician rather than reasons to avoid the drug:

• People with a history of arrhythmias, such as atrial fibrillation or supraventricular tachycardia.
• People whose resting heart rate is already near the top of the normal range.
• People with heart failure or other heart conditions where heart rate is part of the treatment plan.
• People on higher doses, given the dose-related tachycardia rates in the Mounjaro label.
• Adolescents, given the larger proportion with 20+ bpm increases in the Wegovy label.
• People prone to dehydration, such as older adults or anyone with ongoing GI side effects.

If you take a beta blocker or another heart-rate-controlling drug, don't change the dose on your own. Our GLP-1 cardiology overview covers questions to raise with a cardiologist.

How to check your own heart rate

1. Get a baseline before or early in treatment. Measure resting heart rate in the morning, seated, after a few minutes of quiet, before caffeine. Do it on several days.
2. Recheck on the same schedule. Once or twice a week is plenty for most people. Note the date, dose, and days since your injection.
3. Compare trends, not single readings. One high number after coffee or a bad night isn't meaningful. A steady rise over a couple of weeks is.
4. Check when you feel off. If you notice palpitations, measure and note what you were doing, plus any dizziness or shortness of breath.
5. Bring the log to appointments. It's far more useful than a single office reading taken after rushing in.

What your clinician may do with the information

A higher reading isn't automatically a reason to stop treatment. When you report a rise, a clinician will usually work through a few questions before deciding anything.

• Is it real and sustained? They'll want several resting readings over time, not one office measurement. This is where your home log helps.
• Is something else driving it? Dehydration, low blood pressure, low blood sugar, anemia, thyroid problems, infection, and stimulants can all raise heart rate. Some of these are easy to check with labs or a review of your intake.
• Is the rhythm normal? If you describe palpitations, skipped beats, or an irregular pulse, an ECG or a wearable heart monitor may be ordered to tell a normal fast rhythm from an arrhythmia.
• Do other medications need adjusting? Weight loss can change your needs for blood pressure and diabetes drugs, which can affect heart rate indirectly.
• Does the dose or pace need to change? Since the Mounjaro label shows tachycardia episodes rising with dose, some clinicians may consider holding at a lower dose. For Wegovy, the label is direct: discontinue if a sustained increase in resting heart rate occurs.

Those are clinical decisions. Your part is to give them good data and report symptoms early, rather than adjusting or skipping doses on your own.

When to call

Contact your prescriber promptly if:

• You feel palpitations or a racing heartbeat while at rest. The Wegovy label specifically asks patients to report this.
• Your resting heart rate is consistently above 100 bpm, or has risen steadily over a couple of weeks.
• A fast heartbeat comes with dizziness on standing, vomiting, diarrhea, or peeing much less, which can point to dehydration.
• You take insulin or a sulfonylurea and a fast heartbeat comes with shakiness, sweating, or confusion.
• You have a known arrhythmia and notice your usual pattern changing.

Questions for your clinician

• What resting heart rate would you want me to report?
• Should we check an ECG or labs, such as thyroid function or electrolytes?
• Are any of my other medications or supplements adding to this?
• Would a slower titration help, or is this a reason to reconsider the drug?

For broader symptom triage, see when to call vs. when to wait.